Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 17
Licensing Agreements 19
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 21
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 23
Equity Offering 25
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 25
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 26
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 28
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 29
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 31
ZIOPHARM Oncology Inc – Key Competitors 33
ZIOPHARM Oncology Inc – Key Employees 34
ZIOPHARM Oncology Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 06, 2017: ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities 36
Jul 31, 2017: ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities 39
May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 42
Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 45
Nov 09, 2016: ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities 47
Aug 09, 2016: ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities 50
May 10, 2016: ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities 52
Feb 24, 2016: ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities 55
Corporate Communications 58
Sep 28, 2017: ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer 58
Legal and Regulatory 59
Jul 15, 2016: Federman & Sherwood Investigates ZIOPHARM Oncology for Possible Violations of Federal Securities Laws 59
Product News 60
11/15/2016: Sleeping Beauty System Used to Co-express CAR with Membrane-Bound IL-15 to Enhance Persistence of CD19-Specific T Cells 60
Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 61
10/10/2016: ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer 62
03/09/2016: Molecular Therapy Publication Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy 63
Feb 23, 2016: ZIOPHARM Announces Publication in Scientific Reports Describing Genetic Editing of Human Leukocyte Antigen in Cell Therapies to Broaden Their Human Application 64
Jan 11, 2016: ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine 65
Clinical Trials 66
Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach 66
Nov 17, 2016: ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer 67
Jul 19, 2016: ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 68
Jul 15, 2016: ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 69
Jul 12, 2016: ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia 70
Jun 27, 2016: ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 71
May 18, 2016: ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 72
Apr 18, 2016: ZIOPHARM Announces Oral Presentation on AdRTSIL-12 at ASGCT 19th Annual Meeting 74
Apr 18, 2016: ZIOPHARM Announces Oral Presentation on Cancer Immunotherapy at ASGCT 19th Annual Meeting 75
Feb 24, 2016: ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase I Study of Ad-RTS-hIL-12 for Advanced Glioma 76
Feb 09, 2016: ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ZIOPHARM Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 21
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 23
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 25
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 26
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 28
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 29
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 31
ZIOPHARM Oncology Inc, Key Competitors 33
ZIOPHARM Oncology Inc, Key Employees 34
ZIOPHARM Oncology Inc, Subsidiaries 35
【免責事項】
http://www.globalresearch.jp/disclaimer